Request Demo

Last update 08 May 2025

RIP-140

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

siRNA

Synonyms-

Target-

Action

inhibitors

Mechanism

Genetic transcription inhibitors

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest Phase-

First Approval Date-

Regulation-

Structure/Sequence

Boost your research with our RNA technology data.

view full example data

100 Clinical Results associated with RIP-140

100 Translational Medicine associated with RIP-140

100 Patents (Medical) associated with RIP-140

Literatures (Medical) associated with RIP-140

01 Jun 2022·NeuroMolecular MedicineQ3 · MEDICINE

Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines

Q3 · MEDICINE

Article

Author: Tsai, Hong-Chieh ; Chen, Pin-Yuan ; Chen, Ko-Ting ; Wang, Hsiang-Tsui ; Huang, Chiung-Yin ; Huang, Chun-Hao ; Lin, Ya-Jui ; Cheng, Hsiao-Wei ; Wei, Kuo-Chen

Glioblastoma (GBM), a grade IV glioma, is responsible for the highest years of potential life lost among cancers. The poor prognosis is attributable to its high recurrence rate, caused in part by the development of resistance to chemotherapy. Receptor-interacting protein 140 (RIP140) is a very versatile coregulator of nuclear receptors and transcription factors. Although many of the pathways regulated by RIP140 contribute significantly to cancer progression, the function of RIP140 in GBM remains to be determined. In this study, we found that higher RIP140 expression was associated with prolonged survival in patients with newly diagnosed GBM. Intracellular RIP140 levels were increased after E2F1 activation following temozolomide (TMZ) treatment, which in turn modulated the expression of E2F1-targeted apoptosis-related genes. Overexpression of RIP140 reduced glioma cell proliferation and migration, induced cellular apoptosis, and sensitized GBM cells to TMZ. Conversely, knockdown of RIP140 increased TMZ resistance. Taken together, our results suggest that RIP140 prolongs the survival of patients with GBM both by inhibiting tumor cell proliferation and migration and by increasing cellular sensitivity to chemotherapy. This study helps improve our understanding of glioma recurrence and may facilitate the development of more effective treatments.

01 Oct 2018·Translational OncologyQ3 · MEDICINE

Importance of RIP140 and LCoR Sub-Cellular Localization for Their Association With Breast Cancer Aggressiveness and Patient Survival

Q3 · MEDICINE

ArticleOA

Author: Vincent Cavaillès ; Christina Kuhn ; Nadia Harbeck ; Katharina Müller ; Jutta Engel ; Stéphan Jalaguier ; Sophie Sixou ; Nina Ditsch ; Udo Jeschke ; Doris Mayr

New markers are needed to improve diagnosis and to personalize treatments for patients with breast cancer (BC). Receptor-interacting protein of 140 kDa (RIP140) and ligand-dependent corepressor (LCoR), two transcriptional co-regulators of estrogen receptors, strongly interact in BC cells. Although their role in cancer progression has been outlined in the last few years, their function in BC has not been elucidated yet. In this study, we investigated RIP140 and LCoR localization (cytoplasm vs nucleus) in BC samples from a well-characterized cohort of patients (n = 320). RIP140 and LCoR were expressed in more than 80% of tumors, (predominantly in the cytoplasm), and the two markers were highly correlated. Expression of RIP140 and LCoR in the nucleus was negatively correlated with tumor size. Conversely, RIP140 and LCoR cytoplasmic expression strongly correlated with expression of two tumor aggressiveness markers: N-cadherin and CD133 (epithelial mesenchymal transition and cancer stem cell markers, respectively). Finally, high RIP140 nuclear expression was significantly correlated with longer overall survival, whereas high total or cytoplasmic expression of RIP140 was associated with shorter disease-free survival. Our study strongly suggests that the role of RIP140 and LCoR in BC progression could vary according to their prevalent sub-cellular localization, with opposite prognostic values for nuclear and cytoplasmic expression. The involvement in BC progression/invasiveness of cytoplasmic RIP140 could be balanced by the anti-tumor action of nuclear RIP140, thus explaining the previous contradictory findings about its role in BC.

01 Sep 2016·Molecular Nutrition & Food ResearchQ2 · AGRICULTURAL & FORESTRY SCIENCE

Combined high‐fat‐resveratrol diet and RIP140 knockout mice reveal a novel relationship between elevated bone mitochondrial content and compromised bone microarchitecture, bone mineral mass, and bone strength in the tibia

Q2 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Ward, Wendy E. ; Miotto, Paula M. ; Wright, David C. ; Holloway, Graham P. ; Frendo‐Cumbo, Scott ; Sacco, Sandra M.

ScopeWhile resveratrol (RSV) is associated with the prevention of high‐fat (HF) diet‐induced insulin resistance, the effects on bone health combined with an HF‐diet is unknown. Therefore, we determined the effect of RSV on bone microarchitecture in the presence of an HF‐diet, while also elucidating molecular adaptations within bone that could contribute to bone health status.Methods and resultsMale C57BL6 mice were provided control (10% fat) or HF‐diet (60% fat) in the presence or absence of RSV for 12 weeks. While RSV prevented HF diet‐induced glucose intolerance, HF‐RSV compromised tibial microarchitecture, mineral mass, and strength. The compromised outcomes following HF‐RSV corresponded with higher markers of osteoclast‐activation and bone‐resorption (decreased OPG/RANKL ratio; increased cathepsin K), as well as higher markers of tibial mitochondrial content. A molecular model of elevated mitochondrial content (RIP140 knock out (KO) mice) was utilized to determine proof‐of‐principle that increasing mitochondrial content coincides with decrements in bone health. RIP140 KO mice displayed higher markers of mitochondrial content, and similar to HF‐RSV, had compromised bone microarchitecture, lower BMD/strength, and higher markers of osteoclast‐activation/bone‐resorption.ConclusionThese data show that in the presence of an HF‐diet, RSV negatively alters bone health, a process associated with increased mitochondrial content and markers of bone resorption.

100 Deals associated with RIP-140

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

RIP-140

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation